[HTML][HTML] Adjuvant therapy in adrenocortical carcinoma: reflections and future directions

S Bedrose, M Daher, L Altameemi, MA Habra - Cancers, 2020 - mdpi.com
Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with high risk of
recurrence despite macroscopically complete surgical resection. The main predictors of …

[HTML][HTML] The impact of angiotensin-converting enzyme 2 (ACE2) expression on the incidence and severity of COVID-19 infection

AO Kaseb, YI Mohamed, AE Malek, II Raad… - Pathogens, 2021 - mdpi.com
The novel coronavirus disease 2019 (COVID-19) pandemic has led to an unprecedented
threat to the international community and raised major concerns in terms of public health …

[HTML][HTML] Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

S Bedrose, KC Miller, L Altameemi, MS Ali… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background There is no effective systemic therapy for metastatic adrenal cortical carcinoma
(ACC) after failure of platinum-based chemotherapy. The efficacies of single-agent oral …

Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

AO Kaseb, HS Tran Cao, YI Mohamed, A Qayyum… - 2020 - ascopubs.org
4599 Background: In resectable hepatocellular carcinoma (HCC) surgical resection is
associated with high recurrence rates. However, there is no approved neoadjuvant or …

Temporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary referral-center experience

M Daher, J Varghese, SK Gruschkus… - The Journal of …, 2022 - academic.oup.com
Context Reporting temporal trends in adrenocortical carcinoma (ACC) helps guide
management strategies. Objective This work aimed to report the trends in disease burden …

[HTML][HTML] Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

YI Mohamed, DG Duda, MO Awiwi, SS Lee… - Oncotarget, 2022 - ncbi.nlm.nih.gov
Introduction: Hepatocellular carcinoma (HCC) has limited systemic therapy options when
discovered at an advanced stage. Thus, there is a need for accessible and minimally …

Recent advances in the development of antibody-drug conjugates in urothelial cancer

O Alhalabi, L Altameemi, MT Campbell… - The Cancer …, 2022 - journals.lww.com
Antibody-drug conjugates (ADCs) have joined the armamentarium against urothelial cancer
(UC) as an effective therapy option. Since 2019, the US Food and Drug Administration has …

The prognostic value of baseline clinical and radiologic imaging features in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus …

MO Awiwi, KM Elsayes, YI Mohamed… - Journal of …, 2022 - Taylor & Francis
Purpose To identify prognostic clinical and radiologic features in patients with unresectable
hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab. Patients and …

[PDF][PDF] MON-491 TRK-fusion thyroid cancer: a clinical overview in a large population at a single cancer center

S Fazeli, R Dadu, SG Waguespack… - Journal of the …, 2020 - academic.oup.com
Introduction: Most thyroid cancers (TC) are due to mutually exclusive somatic driver
mutations. NTRK fusions are rare oncogenic drivers in papillary TC (PTC), poorly …

ORGANIZING PNEUMONITIS AS A FATAL ADVERSE EFFECT OF TEMOZOLOMIDE: A CASE REPORT AND REVIEW OF THE LITERATURE

H Lakshman, J Alward, L Altameemi, A Chandran - Chest, 2021 - journal.chestnet.org
DISCUSSION: Temozolomide is an oral alkylating agent that has been used in combination
with radiation therapy in improving disease progression-free survival in patients with …